How does abatacept really work in rheumatoid arthritis?
Authors:
- Michael BonelliMBMichael Bonelli
- Clemens ScheineckerCSClemens Scheinecker
- 1 May 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 30 (3) , 295-300
Abstract
Purpose of review: The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis. Recent findings: Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells. In humans, Abatacept treatment was shown to be effective in patients with various autoinflammatory diseases including rheumatoid arthritis. Although the prevention of T-cell activation by interfering with signaling via CD28 still represents the main mechanism of action Abatacept acts on additional cell populations including regulatory T cells (Treg), monocytes/macrophages, osteoclasts, and B cells. Summary: Effects of Abatacept on other cell populations besides T cells have to be taken into account and might represent a valuable contribution to the therapeutic success.Keywords
This publication has 42 references indexed in Scilit:
- CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patientsBMC Immunology, 2013
- Abatacept (CTLA‐4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritisArthritis & Rheumatism, 2012
- B lymphocyte cytokines and rheumatic autoimmune diseaseArthritis & Rheumatism, 2009
- T-cell co-stimulatory pathways in autoimmunityArthritis Research & Therapy, 2008
- CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase FunctionJournal of Experimental Medicine, 2004
- Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2European Journal of Immunology, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Elevated expression of cd80 (b7/bb1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritisArthritis & Rheumatism, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cellsin vitroEuropean Journal of Immunology, 1993